Marine Perrier

Marine Perrier

Auto-generated profile, based on publicly available information

Marine Perrier

IAME, UMR 1137, INSERM, Université Paris Diderot, Sorbonne Paris Cité, AP-HP, Laboratoire de Virologie, Hôpital Bichat, AP-HP, Paris, France

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
CCCharlotte Charpentier
Charlotte Charpentier
BMBrigitte Montes
Brigitte Montes
MPMarine Perrier
Marine Perrier
NMNadia Meftah
Nadia Meftah
JRJacques Reynes
Jacques Reynes
The DOLULAM study assessed the efficacy of dolutegravir + lamivudine dual therapy to maintain virological suppression in heavily treatment-experienced HIV-1-infected adults. No virological failure occurred during the first year of the dual therapy. A virological substudy was conducted to assess the prevalence of M184I/V mutations at dual therapy initiation using historical DNA/RNA genotypes and baseline DNA genotype obtained by next-generation sequencing (NGS). HIV-1 RT sequences were obtained from DNA and/or historical RNA using Sanger technology. HIV-1 DNA RT and integrase NGS was performed using Illumina® technology. Among the 27 patients enrolled in the DOLULAM study, historical HIV DNA and RNA Sanger sequences were available in 14 and 18 patients, respectively. At the initiation of DOLULAM, DNA NGS genotypes showed that 45% and 21% of the patients harboured minority resistant variants (MRV) in RT and integrase, respectively. Combining all available genotype data, an M184I/V was observed in 17 of 27 (63%) of the patients. Most M184V were detected in historical RNA genotypes (n = 8 of 11), whereas M184I were exclusively detected in DNA genotypes (n = 10, including 7 as MRV). Ten patients displayed defective viral genomes in cellular reservoirs, all including M184I and stop codons. At the time of DOLULAM initiation, M184V was observed in DNA NGS in five patients, including one as MRV. These first NGS data on HIV DNA at initiation of a switch study showed (i) a high proportion of patients harbouring defective viral genomes, whose mutation M184I is a marker, and (ii) a low number of patients in whom M184V remained as a major viral variant in PBMCs.

4 July 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MPMarine Perrier
Marine Perrier
MBMélanie Bertine
Mélanie Bertine
QHQuentin Le Hingrat
Quentin Le Hingrat
VJVéronique Joly
Véronique Joly
BVBenoit Visseaux
Benoit Visseaux
CCCharlotte Charpentier
Charlotte Charpentier

25 October 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MPMarine Perrier
Marine Perrier
BVBenoit Visseaux
Benoit Visseaux
RLRoland Landman
Roland Landman
VJVéronique Joly
Véronique Joly
ETEve Todesco
Eve Todesco
CCCharlotte Charpentier
Charlotte Charpentier
To evaluate, in a clinical cohort of HIV-1-infected patients, the prevalence of PI minority resistant variants (MRV) at ART baseline and their impact on the virological response to a first-line PI-based regimen. In an observational single-centre cohort, we assessed all ART-naive patients initiating a first-line regimen including two NRTI and one boosted PI, darunavir/ritonavir or atazanavir/ritonavir, between January 2012 and March 2015. Ultra-deep sequencing of the pol gene was performed using Illumina® technology. Protease mutations were identified using the WHO transmitted drug resistance list and major PI resistance mutations (IAS-USA drug resistance mutations list). Ninety-four and 16 patients initiating a darunavir/ritonavir-based regimen and an atazanavir/ritonavir-based regimen, respectively, were assessed. Twenty-eight percent of the patients were HIV-1 subtype B, 39% CRF02_AG and 33% other non-B subtypes. Thirteen patients (13.8%) in the darunavir group and three patients (18.8%) in the atazanavir group experienced a virological failure (VF). Overall, 13 (11.8%) subjects had PI MRV at baseline in the median proportion of 1.3% (IQR = 1.1–1.7). The most prevalent PI MRV were G73C (n = 5) and M46I (n = 3). The proportion of patients harbouring baseline PI MRV was similar between those with virological success (10.6%) and those experiencing VF (18.8%) (P = 0.40). No difference was observed in the rate of PI MRV by viral subtype (P = 0.51) or by PI drug (P = 0.40). This study showed a prevalence of 11.8% of PI MRV among 110 ART-naive subjects, without significant impact on the virological response to a first-line PI-based regimen containing darunavir or atazanavir.

8 March 2018 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
CCCharlotte Charpentier
Charlotte Charpentier
GPGilles Peytavin
Gilles Peytavin
MLMinh P Lê
Minh P Lê
VJVéronique Joly
Véronique Joly
OCOrnella Cabras
Ornella Cabras
RLRoland Landman
Roland Landman
To assess, in a clinical cohort, the efficacy of switching current ART in virologically suppressed patients to a dolutegravir-based regimen, regardless of the genotypic susceptibility score (GSS). This was an observational single-centre study assessing ART-treated patients with plasma viral load (pVL) <50 copies/mL who were switched to a dolutegravir-based regimen with 1 year of follow-up. PCR negative was defined as an undetected PCR signal. Trough plasma concentration (C24) was determined using UPLC-MS/MS. Two hundred and thirty-nine patients initiated a dolutegravir-based regimen: 12%, 29% and 59% had a total GSS of 1 or 1.5 (group 1), 2 or 2.5 (group 2) and 3 (group 3), respectively. At switch initiation, the median time since first ART and the median duration with pVL <50 copies/mL were 13 years (IQR = 6–19) and 3 years (IQR = 1–6), respectively. Median times since last genotype were 9, 10 and 5 years for groups 1, 2 and 3, respectively. Twenty patients (8.4%) discontinued the dolutegravir-based regimen due to adverse events. During the study, 96.4% (n = 661/686) of all pVL were 50 copies/mL) without emergence of resistance; these patients’ GSSs were 2, 2.5, 3 and 3. The median dolutegravir C24 was 1545 ng/mL (IQR = 1150–2097). Of the patients with pVL <20 copies/mL, 72% were PCR negative during the follow-up, with no difference between the three groups of patients. This observational cohort study showed a high level of virological suppression maintenance in the first year following the switch to a dolutegravir-based regimen, even in patients with GSS ≤2.

1 July 2016 in Journal of Virological Methods
Verified
Journal Article
Closed access
MPMarine Perrier
Marine Perrier
NDNathalie Désiré
Nathalie Désiré
CDClaire Deback
Claire Deback
HAHenri Agut
Henri Agut
DBDavid Boutolleau
David Boutolleau
Sonia BURRELSonia BURREL
Sonia BURREL

10 February 2017 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
MPMarine Perrier
Marine Perrier
CCCharlotte Charpentier
Charlotte Charpentier
GPGilles Peytavin
Gilles Peytavin
MLMinh Lê
Minh Lê
LBLouis Blondel
Louis Blondel
RLRoland Landman
Roland Landman
Objectives: To assess, in a clinical cohort, the efficacy of switching current ART in virologically suppressed patients to elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as a single-tablet regimen (STR) using the PCR signal of the plasma viral load (pVL) assay and determination of plasma drug concentration (C24). Patients and methods: This was an observational single-centre study enrolling antiretroviral-treated patients with pVL 45 ng/mL, the protein-adjusted IC95. Conclusions: In this clinical cohort of virologically suppressed patients switching to STR, most subjects had adequate elvitegravir C24 values with a high proportion maintaining virological suppression with no residual viraemia until W48.